| Variable . | Total Scans (Positive Scans) (n) . | Sensitivity, % . |
|---|---|---|
| EUS | 59 (41) | 70 |
| CT | 55 (26) | 47 |
| US | 45 (18) | 40 |
| MRI | 33 (19) | 58 |
| SRS | 15 (4) | 27 |
| 68Gallium-PET/CT | 2 (1) | 50 |
| 18FDG-PET/CT | 1 (0) | 0 |
| PTVS | 10 (9) | 90 |
| ASVS | 20 (13) | 65 |
| Intraoperative US | 72 (64) | 89 |
| Variable . | Total Scans (Positive Scans) (n) . | Sensitivity, % . |
|---|---|---|
| EUS | 59 (41) | 70 |
| CT | 55 (26) | 47 |
| US | 45 (18) | 40 |
| MRI | 33 (19) | 58 |
| SRS | 15 (4) | 27 |
| 68Gallium-PET/CT | 2 (1) | 50 |
| 18FDG-PET/CT | 1 (0) | 0 |
| PTVS | 10 (9) | 90 |
| ASVS | 20 (13) | 65 |
| Intraoperative US | 72 (64) | 89 |
Sensitivity of imaging and invasive procedures in 80 patients with insulinoma.
Abbreviations: FDG, fluorodeoxyglucose; SRS, somatostatin receptor scintigraphy.
| Variable . | Total Scans (Positive Scans) (n) . | Sensitivity, % . |
|---|---|---|
| EUS | 59 (41) | 70 |
| CT | 55 (26) | 47 |
| US | 45 (18) | 40 |
| MRI | 33 (19) | 58 |
| SRS | 15 (4) | 27 |
| 68Gallium-PET/CT | 2 (1) | 50 |
| 18FDG-PET/CT | 1 (0) | 0 |
| PTVS | 10 (9) | 90 |
| ASVS | 20 (13) | 65 |
| Intraoperative US | 72 (64) | 89 |
| Variable . | Total Scans (Positive Scans) (n) . | Sensitivity, % . |
|---|---|---|
| EUS | 59 (41) | 70 |
| CT | 55 (26) | 47 |
| US | 45 (18) | 40 |
| MRI | 33 (19) | 58 |
| SRS | 15 (4) | 27 |
| 68Gallium-PET/CT | 2 (1) | 50 |
| 18FDG-PET/CT | 1 (0) | 0 |
| PTVS | 10 (9) | 90 |
| ASVS | 20 (13) | 65 |
| Intraoperative US | 72 (64) | 89 |
Sensitivity of imaging and invasive procedures in 80 patients with insulinoma.
Abbreviations: FDG, fluorodeoxyglucose; SRS, somatostatin receptor scintigraphy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
